{"protocolSection": {"identificationModule": {"nctId": "NCT01192139", "orgStudyIdInfo": {"id": "CV181-111"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)", "officialTitle": "Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN) Coadministered to Healthy Subjects in a Fed Condition"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-11"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-30", "studyFirstSubmitQcDate": "2010-08-30", "studyFirstPostDateStruct": {"date": "2010-08-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-11", "resultsFirstSubmitQcDate": "2011-04-19", "resultsFirstPostDateStruct": {"date": "2011-05-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-04", "lastUpdatePostDateStruct": {"date": "2015-05-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/500 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana \\[IN\\]) to coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, IN) in fed healthy subjects.", "detailedDescription": "This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/500 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, Indiana)"}, "conditionsModule": {"conditions": ["Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "5 mg saxagliptin + a single 500 mg metformin XR tablet", "type": "EXPERIMENTAL", "interventionNames": ["Drug: saxagliptin", "Drug: metformin XR"]}, {"label": "FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)", "type": "EXPERIMENTAL", "description": "under fed state", "interventionNames": ["Drug: saxagliptin + metformin XR (FDC tablet)"]}, {"label": "FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)", "type": "EXPERIMENTAL", "description": "under fasted state", "interventionNames": ["Drug: saxagliptin + metformin XR (FDC tablet)"]}], "interventions": [{"type": "DRUG", "name": "saxagliptin", "description": "Tablets, Oral, 5 mg, once daily, Single dose", "armGroupLabels": ["5 mg saxagliptin + a single 500 mg metformin XR tablet"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "metformin XR", "description": "Tablets, Oral, 500 mg. once daily, Single dose", "armGroupLabels": ["5 mg saxagliptin + a single 500 mg metformin XR tablet"], "otherNames": ["Glucophage XR"]}, {"type": "DRUG", "name": "saxagliptin + metformin XR (FDC tablet)", "description": "Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose", "armGroupLabels": ["FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)", "FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Saxagliptin Observed Maximum Plasma Concentration (Cmax)", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Metformin AUC(0-inf)", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Metformin Cmax", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}], "secondaryOutcomes": [{"measure": "Saxagliptin Terminal Half-life (T1/2)", "description": "terminal half life; calculated as ln(2)/Kel", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 AUC(0-inf)", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 AUC(0-t)", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 Cmax", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 T1/2", "description": "terminal half life; calculated as ln(2)/Kel", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 Tmax", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)", "timeFrame": "Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)"}, {"measure": "Metformin AUC(0-t)", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "timeFrame": "Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)"}, {"measure": "Metformin T1/2", "description": "terminal half life; calculated as ln(2)/Kel", "timeFrame": "Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)"}, {"measure": "Metformin Tmax", "timeFrame": "Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)"}, {"measure": "Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])", "timeFrame": "Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)"}, {"measure": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "timeFrame": "AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later."}, {"measure": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.", "timeFrame": "From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations\n* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive\n* Ages 18 to 45, inclusive\n\nExclusion Criteria:\n\n* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population\n* Major surgical procedure within 4 weeks prior to randomization\n* Positive serology test for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease\n* History of gastrointestinal disease within the past 3 months\n* Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator\n* Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization\n* Unable to tolerate oral and/or intravenous (IV) medications\n* Unable to tolerate the puncturing of veins for drawing of blood\n* Known allergy or hypersensitivity to any component of the study medication\n* History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)\n* Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization\n* Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization\n* Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Ppd Development, Lp", "city": "Austin", "state": "Texas", "zip": "78744", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}]}, "referencesModule": {"references": [{"pmid": "21819160", "type": "DERIVED", "citation": "Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig. 2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants underwent screening evaluations to determine eligibility within 21 days before dosing, and were admitted to the clinical facility the evening before dosing (Day -1). On Day 1 of Period 1, a total of 30 participants who met all of the inclusion and none of the exclusion criteria were randomly assigned to 1 of 6 treatment sequences.", "groups": [{"id": "FG000", "title": "Treatment Sequence ABC", "description": "Treatment A (period 1): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment B (period 2): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment C (period 3): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions. Participants underwent at least a 3-day washout period between each treatment."}, {"id": "FG001", "title": "Treatment Sequence ACB", "description": "Treatment A (period 1): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment C (period 2): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment B (period 3): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions. Participants underwent at least a 3-day washout period between each treatment."}, {"id": "FG002", "title": "Treatment Sequence BAC", "description": "Treatment B (period 1): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment A (period 2): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment C (period 3): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions. Participants underwent at least a 3-day washout period between each treatment."}, {"id": "FG003", "title": "Treatment Sequence BCA", "description": "Treatment B (period 1): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment C (period 2): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment A (period 3): 5 mg saxagliptin + a single 500 mg metformin XR tablet. Participants underwent at least a 3-day washout period between each treatment."}, {"id": "FG004", "title": "Treatment Sequence CAB", "description": "Treatment C (period 1): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment A (period 2): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment B (period 3): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions. Participants underwent at least a 3-day washout period between each treatment."}, {"id": "FG005", "title": "Treatment Sequence CBA", "description": "Treatment C (period 1): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment B (period 2): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment A (period 3): 5 mg saxagliptin + a single 500 mg metformin XR tablet. Participants underwent at least a 3-day washout period between each treatment."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Enrolled and Treated Participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.1", "spread": "8.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.0", "spread": "9.22"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78.31", "spread": "13.74"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.97", "spread": "3.07"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "107.28", "spread": "25.13"}, {"groupId": "OG001", "value": "111.72", "spread": "26.55"}, {"groupId": "OG002", "value": "103.35", "spread": "23.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "1.039", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.011", "ciUpperLimit": "1.068", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Lack of food effect was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.", "paramType": "Ratio of Least Squares Means", "paramValue": "1.078", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.049", "ciUpperLimit": "1.108", "estimateComment": "Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "104.65", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "108.74", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares mean for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "100.84", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Saxagliptin Terminal Half-life (T1/2)", "description": "terminal half life; calculated as ln(2)/Kel", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.46", "spread": "2.85"}, {"groupId": "OG001", "value": "8.56", "spread": "3.04"}, {"groupId": "OG002", "value": "9.21", "spread": "3.91"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "105.47", "spread": "24.98"}, {"groupId": "OG001", "value": "109.88", "spread": "26.36"}, {"groupId": "OG002", "value": "101.52", "spread": "23.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio of Geometric Least Squares Mean", "paramValue": "1.039", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.011", "ciUpperLimit": "1.068", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "1.080", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.051", "ciUpperLimit": "1.110", "estimateComment": "Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "102.84", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "106.89", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares mean for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "98.99", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Saxagliptin Observed Maximum Plasma Concentration (Cmax)", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.84", "spread": "8.26"}, {"groupId": "OG001", "value": "27.25", "spread": "7.95"}, {"groupId": "OG002", "value": "28.85", "spread": "8.62"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "1.021", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.940", "ciUpperLimit": "1.109", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Lack of food effect was concluded if the fed to fasted ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin.", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "0.949", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.873", "ciUpperLimit": "1.031", "estimateComment": "Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "25.68", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "26.21", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares mean for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "27.63", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.65", "spread": "0.65"}, {"groupId": "OG001", "value": "1.48", "spread": "0.75"}, {"groupId": "OG002", "value": "0.65", "spread": "0.50"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.983", "spread": "0.006"}, {"groupId": "OG001", "value": "0.983", "spread": "0.006"}, {"groupId": "OG002", "value": "0.982", "spread": "0.008"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 AUC(0-inf)", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "291.72", "spread": "79.21"}, {"groupId": "OG001", "value": "295.94", "spread": "75.40"}, {"groupId": "OG002", "value": "289.06", "spread": "66.89"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 AUC(0-t)", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "284.46", "spread": "78.25"}, {"groupId": "OG001", "value": "289.03", "spread": "74.80"}, {"groupId": "OG002", "value": "281.79", "spread": "65.91"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 Cmax", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "49.71", "spread": "16.94"}, {"groupId": "OG001", "value": "49.28", "spread": "14.59"}, {"groupId": "OG002", "value": "49.09", "spread": "15.46"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 T1/2", "description": "terminal half life; calculated as ln(2)/Kel", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.88", "spread": "1.53"}, {"groupId": "OG001", "value": "13.65", "spread": "1.72"}, {"groupId": "OG002", "value": "14.04", "spread": "1.33"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 Tmax", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.38", "spread": "0.76"}, {"groupId": "OG001", "value": "2.42", "spread": "0.88"}, {"groupId": "OG002", "value": "1.46", "spread": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.974", "spread": "0.008"}, {"groupId": "OG001", "value": "0.975", "spread": "0.008"}, {"groupId": "OG002", "value": "0.974", "spread": "0.006"}]}]}]}, {"type": "PRIMARY", "title": "Metformin AUC(0-inf)", "description": "Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \\[calculated using the linear trapezoidal rule\\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant", "populationDescription": "Treated participants (the smaller sample size for AUC\\[0-inf\\] was due to the inability to estimate potassium chloride for some participants)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5865.92", "spread": "2357.15"}, {"groupId": "OG001", "value": "5516.97", "spread": "2423.08"}, {"groupId": "OG002", "value": "5073.70", "spread": "1406.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 96% and 97% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.", "paramType": "Ratio of Least Squares Geometric Means", "paramValue": "0.915", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.836", "ciUpperLimit": "1.002", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "lack of food effect concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.", "paramType": "Ratio of Geometric LS Mean and 90% CI", "paramValue": "1.010", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.918", "ciUpperLimit": "1.111", "estimateComment": "Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "5542.2", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "5072.9", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares mean for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "5023.3", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Metformin AUC(0-t)", "description": "Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5617.39", "spread": "2181.99"}, {"groupId": "OG001", "value": "5200.46", "spread": "2203.34"}, {"groupId": "OG002", "value": "4896.95", "spread": "1340.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio of Geometric Least Squares Mean", "paramValue": "0.920", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.854", "ciUpperLimit": "0.992", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "1.025", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.951", "ciUpperLimit": "1.105", "estimateComment": "Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "5287.1", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "4866.2", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares means for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "4746.8", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Metformin Cmax", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "629.73", "spread": "160.14"}, {"groupId": "OG001", "value": "586.87", "spread": "150.63"}, {"groupId": "OG002", "value": "657.23", "spread": "187.67"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 96% and 97% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of metformin.", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "0.933", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.865", "ciUpperLimit": "1.007", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Lack of food effect was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(inf) of saxagliptin and metformin.", "paramType": "Ratio of Geometric Least Squares Means", "paramValue": "0.898", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.832", "ciUpperLimit": "0.969", "estimateComment": "Ration = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "608.41", "ciPctValue": "95"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "567.85", "ciPctValue": "95"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares mean for treatment C", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "632.39", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Metformin T1/2", "description": "terminal half life; calculated as ln(2)/Kel", "populationDescription": "Treated participants (the smaller sample size for T1/2 was due to the inability to estimate Kel for some of the subjects).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.7", "spread": "5.90"}, {"groupId": "OG001", "value": "12.6", "spread": "7.05"}, {"groupId": "OG002", "value": "14.9", "spread": "7.40"}]}]}]}, {"type": "SECONDARY", "title": "Metformin Tmax", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.78", "spread": "1.04"}, {"groupId": "OG001", "value": "4.90", "spread": "1.13"}, {"groupId": "OG002", "value": "4.11", "spread": "0.88"}]}]}]}, {"type": "SECONDARY", "title": "Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])", "populationDescription": "Treated participants (the smaller sample size for AUC(0-inf) was due to the inability to estimate Kel for some of the subjects).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.979", "spread": "0.020"}, {"groupId": "OG001", "value": "0.970", "spread": "0.026"}, {"groupId": "OG002", "value": "0.965", "spread": "0.031"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "populationDescription": "Safety Population = all participants who received any study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"title": "Number of Participants With At Least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Discontinuation Due to an AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)", "groups": [{"id": "OG000", "title": "Treatment A - Saxagliptin + Metformin XR, Fed", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions"}, {"id": "OG001", "title": "Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed", "description": "fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions"}, {"id": "OG002", "title": "Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"title": "Clinical Laboratory Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Vital Sign Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Physical Examination Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "12-Lead ECG Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Treatment A", "description": "5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 3, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Treatment C", "description": "FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 4, "otherNumAtRisk": 30}, {"id": "EG002", "title": "Treatment B", "description": "Fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 2, "otherNumAtRisk": 30}], "otherEvents": [{"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 30}]}, {"term": "PRESYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 30}]}, {"term": "DRY MOUTH", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "FLATULENCE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 30}]}, {"term": "CHAPPED LIPS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "CONSTIPATION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 30}]}, {"term": "LIP SWELLING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "ABDOMINAL DISTENSION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 30}]}, {"term": "DYSURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 30}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}